..., instructions or products referred to in the content or advertisements. Craniopharyngioma Hypothalamus Infundibulum Papillary craniopharyngioma Pituitary tumors Third ventricle The squamous-papillary, or papillary, craniopharyngioma (PCP) is one of the two histological craniopharyngioma (CP...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Dopamine agonist-resistant prolactinomas Management MicroRNAs Pituitary tumors Transforming growth factor-β signaling Dopamine agonists (DAs) are preferred...

... critical for GTPase activity, preventing hydrolysis of GTP and leading to constitutive activation of Gsα. PitNETs, pituitary neuroendocrine tumors; PDE, phosphodiesterase; AC, adenylyl cyclase; GH, growth hormone. Pituitary tumors Pathogenesis Clinical behavior Genetic alterations Filamin...

... Craniopharyngioma Hypopituitarism Imaging Pituitary tumors Pregnancy Reproduction There are two subtypes of CP: aCP and papillary CP (pCP) [ 15, 16 ]. The BRAF V600E mutation is characteristic of pCP, while most of aCP harbor a mutation of the β-catenin gene [ 15, 17 ]. ACP has a high incidence...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pituitary surgery Pituitary-adrenal system Pituitary tumors Neurosurgery Adrenal insufficiency Although transsphenoidal surgery (TS...

..., nonfunctioning pituitary tumors, and PitNET cell-lines (AtT20/GH3-cells). Results: All statins decreased AtT20-cell proliferation, simvastatin showing stronger effects. Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion...

..., instructions or products referred to in the content or advertisements. Hyponatremia Hypernatremia Pituitary tumors Children In C/RSW, the hypovolemic stimulus is more effective on AVP secretion than the hypo-osmolar one; the subsequent compensatory AVP release is then responsible...

..., a second-generation selective ATP-competitive mTOR inhibitor, in non-functioning pituitary tumor cells. During characterization of the molecular mechanisms that mediate Torin1 actions, there seemed to be a rationale for combining it with rapalogs. Methods: Proliferation assays, flow cytometry and Western...

... human disease due to insufficient (hypopituitarism) or excess (pituitary tumor) cell numbers. The pituitary gland produces six different hormones from five secretory cell lineages: GH (produced by somatotrophs), PRL (lactotrophs), TSH (thyrotrophs), ACTH (corticotrophs), FSH and LH (gonadotrophs...

... with corticosteroids, levothyroxine and recombinant human GH; (3) PRL and GH co-secreting pituitary tumors, and (4) suspicion of drug or alcohol abuse. Patients with treatment duration <12 months and those discontinuing CAB for a period >1 month were not considered for the final analysis. Similarly, patients...

..., resistance to conventional treatment leading to early and frequent recurrences. Even more rarely, pituitary tumors can give rise to cerebrospinal or systemic metastases qualifying as pituitary carcinomas according to the latest WHO definition. In the same classification, a subset of tumors with relatively...

... hypogonadism, (3) hypopituitarism without or on replacement treatment with corticosteroids, sexual steroids, levothyroxine and recombinant human GH, (4) PRL and GH co-secreting pituitary tumors, and (5) suspicion of drug or alcohol abuse. Patients with a treatment duration shorter than 12 months, patients who...

... the withdrawal of OCT-LAR for at least 3 months in those patients who had achieved such goal. Evaluation of Treatment Efficacy Acromegaly Somatostatin analogs Octreotide Pituitary tumors Somatostatin Long-acting release octreotide Cabergoline The criterion used to determine the efficacy...

...Gerardo G. Piroli; Claudia A. Grillo; Monica G. Ferrini; Victoria Lux-Lantos; Alejandro F. De Nicola It is known that chronic exposure of F 344 rats to diethylstilbestrol (DES) induces prolactin (PRL)-secreting pituitary tumors composed of proliferating mammotropic cells. In the present work, we...

...Gerardo Piroli; Claudia Grillo; Monica Ferrini; Graciela Díaz-Torga; Estela Rey; Carlos Libertun; Alejandro F. De Nicola We previously reported a reduction of glucocorticoid receptors (GCR) in diethylstilbestrol-induced pituitary tumors (DES-T) in rats. Presently, we found that bromocriptine (BROM...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Growth hormone Glucocorticoids Acromegaly Pituitary tumors Clinical Neuroendocrinology Neuroendocrinology 1993;58...

... from transplantable PRL-secreting pituitary tumors in rats. In 8 patients with invasive PRL-secreting pituitary adenomas with extrasellar extension, the effect of the administration of tamoxifen was investigated on the plasma PRL concentration and on the bromocriptine-mediated inhibition of PRL release...

... Antiestrogens Dopamine Pituitary tumors Tamoxifen Nitromifene citrate Neuroendoerinology 30: 389-395 (1980) Effect of Antiestrogens on Pituitary Prolactin Production in Normal and Pituitary Tumor-Bearing Rats1 Ivan Nagy, Carlos A. Valclenegro and Robert M. MacLeod Department of Internal Medicine...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Carney complex Multiple endocrine neoplasias Pituitary tumors Adrenal...

... factor in most solid tumors, little is known about its production and regulation in pituitary adenomas. We have investigated basal and stimulated VEGF production by rodent pituitary tumor cells (mouse corticotrope AtT20, rat lactosomatotrope GH3, mouse gonadotrope αT3-1 and mouse folliculostellate TtT/GF...